Ranbaxy Laboratories is reportedly in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc’s heartburn drug Nexium, after a US ban on shipments from a plant in India. Nexium had global sales last year of $3.87 billion.
Earlier in January, Washington prohibited Ranbaxy, from selling drugs in the United States using ingredients from one of its plants in northern India due to poor manufacturing practices.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
